NPS Pharma Holdings Ltd.

Philippe Dro, Luciole Medical, and Kush Parmar, 5AM Ventures, named to Board of Directors SCHLIEREN, Switzerland and BOSTON, July 12, 2022 /PRNewswire/ -- GlycoEra AG announced today key appointments of biotech industry leaders to its Board of Directors, including Georges Gemayel, Ph.D., as Chair, as well as Philippe Dro, Ph.D., M.B.A., and Kush Parmar, M.D., Ph.D. Dr. Gemayel is an industry veteran with more than 30 years' experience including global management, executive positions and a range of board appointments. Dr. Dro is Chairman of the Board and Chief Executive Officer at Luciole Medical and has deep experience in biotech business strategy at various emerging biotechnology and medtech companies. Dr. Parmar is a physician-scientist and Managing Partner at 5AM Ventures, where he is focused on building next-generation life science companies. "I am thrilled to welcome Georges, Philippe, and Kush to the GlycoEra Board of Directors as GlycoEra continues to grow and assemble a world-class team to realize the full potential of our CustomGlycan glycoengineering platform," said Ganesh V. Kaundinya, Ph.D., President and Chief Executive Officer of GlycoEra. "Georges' international biopharmaceutical leadership experience and track record of developing successful medicines will prove invaluable as we build a high-value pipeline of medicines. In addition, both Philippe and Kush bring strategic, business and company building expertise to help guide our trajectory of growth." Dr. Gemayel served as President and CEO of Altus Pharmaceuticals, Executive Vice President at Genzyme Corporation, and Vice President, National Specialty Care at Roche Labs Inc. Dr. Gemayel is currently the Chair of the Boards of Dynacure, Gemini Therapeutics, and Enterome SA. Previously, Dr. Gemayel served as Executive Chair of FoldRx Pharmaceuticals and of Syndexa Pharmaceuticals, as Chair of Dimension Therapeutics, OxThera, Orphazyme A/S and Epitherapeutics, and as Director of Prosensa, Raptor Pharmaceuticals, NPS Pharma, Momenta Pharmaceuticals, and Adolor. Dr. Gemayel completed his doctorate in pharmacy at St. Joseph University in Beirut, Lebanon and earned a Ph.D. in pharmacology at Paris-Sud University in Paris, France. "I am impressed with the power of the CustomGlycan Platform to create a portfolio of novel biological products that degrade circulating and membrane proteins in a highly selective and targeted fashion. Removing and degrading disease-causing proteins has broad potential therapeutic applications across autoimmune diseases, oncology, neurology, allergy, and infectious diseases," said Dr. Gemayel. "I am excited to collaborate with the experienced leadership team and Board, including Philippe and Kush, to deliver on our shared vision of developing novel biologics for a wide range of indications." In addition to Dr. Gemayel, Drs. Dro and Parmar bring years of experience and deep knowledge in biotech leadership to GlycoEra: Dr. Philippe Dro, Chairman of the Board and Chief Executive Officer, Luciole Medical Dr. Dro has deep experience initiating and executing strategic transactions at various emerging biotechnology and medtech companies. He is currently Chairman of the Board and CEO at Luciole Medical, while also serving on the Board of several life science companies. He was CEO and member of the Supervisory Board at GlycoVaxyn AG prior to its acquisition by GlaxoSmithKline. Previously, Dr. Dro was CEO and Chairman of the Board of Endoart SA, where he led the company through a successful turnaround resulting in its acquisition by Allergan. He also was a member of the founding team at Axovan, a biotechnology company acquired by Actelion in 2003. Prior to that, he served in management positions at Novartis, SkyePharma, and Antares Pharma. Dr. Kush Parmar, Managing Partner, 5AM Ventures Dr. Parmar currently serves as a Director on the Boards of both private and public companies, including Akouos, Ensoma, Entrada Therapeutics, Homology Medicines, Rallybio, and Vor Biopharma. He previously served as Board Member or Observer for Achaogen, Arvinas, Audentes, Envoy (acquired by Takeda), and scPharmaceuticals, and as Acting VP of Strategy and Corporate Development at Novira (acquired by Johnson & Johnson). Dr. Parmar serves on the Advisory Boards of Penn Medicine, Princeton University's Department of Molecular Biology, and the Grace Science Foundation, and is a fellow of the Society of Kauffman Fellows. Drs. Gemayel, Dro, and Parmar join Monique Schiersing of Roche Venture Fund, Graziano Seghezzi of Sofinnova Partners, and Dr. Kaundinya on the Board of Directors. About GlycoEra AG GlycoEra AG is a biotechnology company building a high-value pipeline of medicines based on deep expertise in glycobiology and protein degradation. GlycoEra's innovative CustomGlycan platform enables the design, engineering, and development of novel biologics for a broad range of indications. GlycoEra is advancing a range of assets toward human clinical studies. The company raised more than $49 million (CHF 45 million) in a 2021 Series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture fund. GlycoEra is based in Schlieren, Switzerland and Boston, Mass., USA. For further information, please visit .

SOMERVILLE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Susan E. Graf has joined Finch’s Board of Directors and will serve as Chair of the Audit Committee. Ms. Graf is an accomplished biopharma executive with more than 25 years of experience spanning corporate strategy, finance, business development, M&A, and the development and commercialization of biopharmaceuticals. “With Finch’s recent IPO, strong Phase 2 data from their lead candidate, and innovative programs in chronic hepatitis B and autism entering the clinic soon, I am thrilled to join Finch at this exciting time,” said Susan Graf. “I look forward to working with Finch’s board and leadership team to execute on Finch’s strategy and its mission to serve patients.” “On behalf of the Finch team, I am delighted to welcome Susan to our board,” said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics. “Susan’s extensive experience and demonstrated ability to guide the strategic growth of organizations and enable the development of new therapeutics will be invaluable as we continue to rapidly advance our pipeline, platform, and this new modality.” Ms. Graf currently serves as Chief Executive Officer of Akamara Therapeutics. Prior to Akamara, she was Chief Business Officer and Principal Financial Officer at Epizyme, Inc., leading finance, investor relations, corporate and business development and alliance management as well as implementing Epizyme’s corporate strategy. Prior to Epizyme, Ms. Graf held the position of Vice President, Corporate Development and Strategy for NPS Pharma before it was acquired by Shire in 2015. She was closely involved in the company’s sale to Shire for $5.2B, in addition to serving on the executive team that transformed NPS Pharma into a global, commercial-stage, rare-disease biopharmaceutical company. During her tenure, NPS Pharma brought two rare disease products – Gattex® and Natpara®– to market. Prior to NPS Pharma, Ms. Graf spent nearly 18 years at Roche in a number of leadership and executive positions in business development, commercial assessment, due diligence, mergers & acquisitions, marketing, market research, sales, and manufacturing. Ms. Graf has an MBA from the Stern School of Business at New York University and a Bachelor of Pharmacy degree from Purdue University. About Finch Therapeutics Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively. Cautionary Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “potential,” "projects,” “would” and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding: the commencement of the chronic hepatitis B and autism clinical trials and Finch’s ability to rapidly advance its pipeline, platform, and the microbiome modality. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Finch’s limited operating history and historical losses; Finch’s ability to raise additional funding to complete the development and any commercialization of its product candidates; Finch’s dependence on the success of its lead product candidates, CP101; Finch’s may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses Finch’s intellectual property position Finch’s ability to qualify and scale its manufacturing capabilities in anticipation of commencement of multiple global clinical trials; Finch’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and risks relating to the impact and duration of the COVID-19 pandemic on Finch’s business. These and other risks are described more fully in Finch’s filings with the Securities and Exchange Commission (“SEC”), including the section titled “Risk Factors” in in Finch’s final prospectus dated March 18, 2021 filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) on March 22, 2021, as well as discussions of potential risks, uncertainties, and other important factors Finch’s subsequent filings with the SEC. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Except to the extent required by law, Finch undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc. Media Contact: Gabriella Linville-Engler media@finchtherapeutics.com Investor Contact: Greg Perry ir@finchtherapeutics.com

$150M Strategic Financing Supports Execution into the First Half of 2023 OTL-203 Achieves Proof of Concept (POC) in MPS-I Hurler Syndrome (MPS-IH); Registrational Trial Planned to Initiate by Year End 2021 OTL-200 U.S. Filing Strategy for Metachromatic Leukodystrophy (MLD) Expected by Mid-2021 R&D Organizational Leadership Changes Announced BOSTON and LONDON, March 02, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today reported financial results for the year ended December 31, 2020, as well as recent accomplishments, 2021 strategic priorities and upcoming milestones, and related organizational leadership updates. Frank Thomas, president and chief operating officer said, “It is gratifying to witness the positive momentum Orchard has already established in early 2021 driven by solid execution. Our compelling data in neurodegenerative disorders at the WORLDSymposium and successful completion of the $150 million financing exemplify this recent progress and showcase a growing appreciation for the potential of HSC gene therapy. We look forward to continuing our work in the year ahead and delivering further benefit for patients and our shareholders." Recent Accomplishments February 2021 Executed a $150 million private investment in public equity (PIPE) financing at a price of $6.22 per share with several existing and new investors with expertise in healthcare, including RA Capital Management, Avidity Partners, Casdin Capital, Farallon Capital, and Surveyor Capital (a Citadel company), among others. The link to the full release is available here. Presented data from multiple neurometabolic programs at the 2021 WORLDSymposium. The link to the full release is available here. Interim data for OTL-203 showing positive clinical results in multiple disease manifestations of MPS-IH was highlighted. All eight patients treated with OTL-203 showed stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment. Treatment with OTL-203 has been generally well-tolerated with a safety profile consistent with the selected conditioning regimen. An oral presentation featuring supportive biomarker data from the first three patients in the ongoing OTL-201 POC study for mucopolysaccharidosis type IIIA (MPS-IIIA, or Sanfilippo syndrome) was also featured. The treatment has been generally well-tolerated in the first three patients with no treatment-related serious adverse events (SAEs), and all transplant-related SAEs and adverse events have resolved. January 2021 Appointed Braden Parker as chief commercial officer. Mr. Parker most recently served as Orchard’s senior vice president and general manager for North America and has more than 20 years of experience in the healthcare industry, including commercial leadership roles at Celgene, NPS Pharma (Shire) and PTC Therapeutics, where he led the company’s U.S. product launch in Duchenne muscular dystrophy and oversaw strategic planning for the gene therapy business. Received Regenerative Medicine Advanced Therapy (RMAT) designation for OTL-200 from the U.S. Food and Drug Administration (FDA) for early-onset MLD. This designation has the potential to enhance regulatory interactions in the U.S. and open an expedited path to a biologics license application (BLA) filing. Secured partnerships with two leading regional specialty pharmaceutical companies to broaden access to Libmeldy (OTL-200) for eligible patients with MLD in the Middle East & Turkey. 2021 Corporate Priorities and Upcoming Milestones Orchard previously outlined the following key corporate objectives and upcoming expected milestones: Build a successful commercial business in hematopoietic stem cell (HSC) gene therapy Launch Libmeldy (OTL-200) for the treatment of eligible patients with early-onset MLD in Europe in the first half of 2021 Complete additional interactions with the FDA by mid-2021 to determine the path to a BLA filing for OTL-200 File an Marketing Authorization Application (MAA) for OTL-103 in Wiskott-Aldrich syndrome (WAS) with the European Medicines Agency by year-end 2021; followed by a BLA filing in the U.S. in 2022 Continue to lead the development of gene therapies for neurodegenerative disorders by advancing two POC programs in MPS-IH and MPS-IIIA Initiate a registrational trial for OTL-203 for MPS-IH by year-end 2021 Complete enrollment in the five-patient POC trial for OTL-201 for MPS-IIIA Present additional clinical data from the OTL-203 and OTL-201 POC trials Investigate the potential of HSC gene therapy in larger indications Announce new preclinical data from research programs in frontotemporal dementia with progranulin mutations (GRN-FTD) and Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD) in the second half of 2021 Organizational Leadership Updates Given the progress on key development programs, Anne Dupraz has been appointed to the expanded role of chief development officer. In addition to overseeing the company’s regulatory strategy, Ms. Dupraz will lead product development with the goal of ensuring a seamless approach to moving Orchard’s programs through to potential regulatory approval. Ms. Dupraz possesses more than 20 years of experience in the clinical and regulatory fields and has deep expertise in advanced therapies, having been involved in more than 50 different tissue, cell and gene-based therapy development programs in her career. Ran Zheng, chief technical officer, and Andrea Spezzi, chief medical officer, are stepping down from their respective leadership positions with Orchard to pursue other opportunities. Orchard has initiated a global search for permanent replacements for both of these roles. Fourth Quarter 2020 Financial Results Research and development expenses were $22.6 million for the three months ended December 31, 2020, compared to $30.9 million in the same period in 2019. R&D expenses include the costs of clinical trials and preclinical work on the company’s portfolio of investigational gene therapies, as well as costs related to regulatory, manufacturing, license fees and milestone payments under the company’s agreements with third parties, and personnel costs to support these activities. The company expects R&D expenses to grow slightly in the upcoming periods as the company continues to advance its programs through later stages of development. Selling, general and administrative expenses were $16.2 million for the three months ended December 31, 2020, compared to $18.5 million in the same period in 2019. The decrease was primarily due to realization of savings associated with an updated strategy and corporate restructuring announced in May 2020. Net loss attributable to ordinary shareholders was $33.6 million for the three months ended December 31, 2020, compared to $45.4 million in the same period in 2019. The decline in net loss as compared to the prior year was primarily due to savings realized in our operating expenses as a result of the company’s updated strategy and corporate restructuring. The company had 98.3 million ordinary shares outstanding as of December 31, 2020. Thomas continued, "Our burn rate has declined from prior periods as we see the positive impact of our May 2020 corporate restructuring take hold, providing a longer runway and greater financial flexibility, aided by our recent financing. We are investing to support execution for the highest value programs in our portfolio while also dedicating capital to our longer-term strategy to expand into larger indications. Cash, cash equivalents and investments as of December 31, 2020, were $191.9 million compared to $325.0 million as of December 31, 2019, with the decrease primarily driven by cash used to fund operations in 2020. In the fourth quarter of 2020, the cash used to fund operations was approximately $12.0 million after the receipt of approximately $19.2 million from R&D tax credit refunds related to 2019 qualifying activities under the tax code in the UK. The company expects that its cash, cash equivalents and investments as of December 31, 2020, along with gross proceeds of $150.0 million from the February 2021 private placement, will support its currently anticipated operating expenses and capital expenditure requirements into the first half of 2023. This cash runway excludes the $50 million available under the company’s credit facility and any non-dilutive capital received from potential future partnerships or priority review vouchers granted by the FDA following future potential U.S. approvals. About Libmeldy / OTL-200 Libmeldy (autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase-A (ARSA) gene), also known as OTL-200, has been approved by the European Commission for the treatment of MLD in eligible early-onset patients characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity in children with i) late infantile or early juvenile forms, without clinical manifestations of the disease, or ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline. Libmeldy is the first therapy approved for eligible patients with early-onset MLD. The most common adverse reaction attributed to treatment with Libmeldy was the occurrence of anti-ARSA antibodies. In addition to the risks associated with the gene therapy, treatment with Libmeldy is preceded by other medical interventions, namely bone marrow harvest or peripheral blood mobilization and apheresis, followed by myeloablative conditioning, which carry their own risks. During the clinical studies, the safety profiles of these interventions were consistent with their known safety and tolerability. For more information about Libmeldy, please see the Summary of Product Characteristics (SmPC) available on the EMA website. Libmeldy is not approved outside of the European Union, UK, Iceland, Liechtenstein and Norway. OTL-200 is an investigational therapy in the US. Libmeldy was developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. About Orchard Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist. Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit , and follow us on Twitter and LinkedIn. Availability of Other Information About Orchard Investors and others should note that Orchard communicates with its investors and the public using the company website (), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchard’s investor relations website and may include additional social media channels. The contents of Orchard’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Forward-Looking Statements This press release contains certain forward-looking statements about Orchard’s strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchard’s business strategy and goals, including its plans and expectations for the commercialization of Libmeldy, the therapeutic potential of Libmeldy (OTL-200) and Orchard’s product candidates, including the product candidates referred to in this release, Orchard’s expectations regarding its ongoing preclinical and clinical trials, including the timing of enrollment for clinical trials and release of additional preclinical and clinical data, the likelihood that data from clinical trials will be positive and support further clinical development and regulatory approval of Orchard's product candidates, and Orchard’s financial condition and cash runway into the first half of 2023. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchard’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the risk that prior results, such as signals of safety, activity or durability of effect, observed from clinical trials of Libmeldy will not continue or be repeated in our ongoing or planned clinical trials of Libmeldy, will be insufficient to support regulatory submissions or marketing approval in the US or to maintain marketing approval in the EU, or that long-term adverse safety findings may be discovered; the risk that any one or more of Orchard’s product candidates, including the product candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchard’s ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchard’s product candidates; the delay of any of Orchard’s regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchard’s product candidates or the receipt of restricted marketing approvals; the inability or risk of delays in Orchard’s ability to commercialize its product candidates, if approved, or Libmeldy, including the risk that Orchard may not secure adequate pricing or reimbursement to support continued development or commercialization of Libmeldy; the risk that the market opportunity for Libmeldy, or any of Orchard’s product candidates, may be lower than estimated; and the severity of the impact of the COVID-19 pandemic on Orchard’s business, including on clinical development, its supply chain and commercial programs. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchard’s quarterly report on Form 10-Q for the quarter ended September 30, 2020, as filed with the U.S. Securities and Exchange Commission (SEC), as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchard’s views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Contacts Investors Renee Leck Director, Investor Relations +1 862-242-0764 Renee.Leck@orchard-tx.com Media Christine Harrison Vice President, Corporate Affairs +1 202-415-0137 media@orchard-tx.com